article thumbnail

STAT+: NYU professors who defended vaping didn’t disclose ties to Juul, documents show

STAT

Abrams, a frequent commentator about vaping in the news media, including CBS This Morning, CNN, and The New Yorker, coordinated extensively with Juul on public messaging in 2017 and 2018, according to company emails.

article thumbnail

STAT+: How sickle cell became the first disease treated by CRISPR

STAT

  The document was supposed to help Novak, then the chief executive of CRISPR Therapeutics, navigate a pressing quandary. “We looked at anything and everything,” said Novak, who stepped down as CEO in 2017 but remained on the board until this year.  But which should they target first?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: SEC wants to know if key supplier of research monkeys bribed foreign officials

STAT

The company — which is a major supplier of non-human primates to corporate, government, and academic research laboratories — received a voluntary request last May for documents dating back to December 2017 about importing non-human primates from Asia, according to a regulatory filing. ( See page 42.)

article thumbnail

STAT+: Brazil dismisses antitrust complaint against Gilead over pricing for a hepatitis C drug

STAT

This purportedly contributed to nearly 6,000 deaths from the disease between 2015 and 2017, according to documents filed with the Administrative Council for Economic Defense. Continue to STAT+ to read the full story…

article thumbnail

The race for a new class of antibiotics

European Pharmaceutical Review

A study on the surge of new antimicrobial research has shown that despite almost a quarter of a million research papers (227,808) being published on the 12 bacterial families in the World Health Organization (WHO) global priority pathogen list of antibiotic-resistant bacteria from 2017, no new class of antibiotics has gone to market since 1987.

article thumbnail

STAT+: Pharmalittle: Chinese drugmakers develop copycat weight loss drugs; SEC eyes supplier of research monkeys

STAT

 The company — which is a major supplier of non-human primates to corporate, government, and academic research laboratories — received a voluntary request last May for documents dating back to December 2017 about importing non-human primates from Asia, according to a regulatory filing.

article thumbnail

Is ASCA worth it? FDA’s Accreditation Scheme for Conformity Assessment

The FDA Law Blog

As part of that effort, Accreditation Scheme for Conformity Assessment (ASCA) is designed to reduce FDA review time, reduce and/or remove Sponsor guesswork on documentation to provide in a premarket submission, and improve the quality of testing conducted. The MDUFA V reauthorization converts the ASCA Pilot to a permanent program.